Double-Barreled immune attack aims to wipe out hidden myeloma cells
NCT ID NCT06993675
First seen May 02, 2026 · Last updated Jun 14, 2026 · Updated 8 times
Summary
This study is for people newly diagnosed with multiple myeloma who still have traces of cancer after initial treatment. It tests two bispecific antibody drugs, talquetamab and teclistamab, given one after the other if needed, to try to make the cancer undetectable. The goal is to achieve a deeper, longer-lasting remission, though the disease is not considered curable and ongoing maintenance therapy is expected.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for MULTIPLE MYELOMA are added.
By submitting, you agree to our Terms of use
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Study contacts
-
Contact
Phone: •••-•••-•••• Email: •••••@•••••
Locations
-
Wilmot Cancer Center, Clinical Trial Office of the University of Rochester Medical Center
NOT_YET_RECRUITINGRochester, New York, 14642, United States
Contact
Contact Phone: •••-•••-•••• Email: •••••@•••••
-
Yale University
RECRUITINGNew Haven, Connecticut, 06519, United States
Contact Phone: •••-•••-•••• Email: •••••@•••••
Contact
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.